<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Serotonin syndrome (serotonin toxicity)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Serotonin syndrome (serotonin toxicity)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Serotonin syndrome (serotonin toxicity)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward W Boyer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Serotonin syndrome, also referred to as serotonin toxicity, is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system. It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning [<a href="#rid1">1</a>]. Although classically described as the triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities, serotonin syndrome is actually a spectrum of clinical findings ranging from benign to lethal [<a href="#rid1">1-4</a>]. A summary table to facilitate the emergent management of serotonin syndrome is provided  (<a class="graphic graphic_table graphicRef73400" href="/z/d/graphic/73400.html" rel="external">table 1</a>).</p><p>This review will discuss serotonin syndrome. A discussion of selective serotonin reuptake inhibitor (SSRI) intoxication and a general approach to management of the poisoned patient are found elsewhere. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/297.html" rel="external">"Selective serotonin reuptake inhibitor poisoning"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p></p><p class="headingAnchor" id="H233679314"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Serotonin syndrome (ie, serotonin toxicity) is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system. It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning [<a href="#rid1">1</a>]. Serotonin syndrome may involve a spectrum of clinical findings, which often include mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. (See <a class="local">'Clinical features'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Serotonin syndrome has been observed in all age groups, including newborns and older adults. The increasing incidence of this condition is thought to parallel the increasing use of serotonergic agents in medical practice [<a href="#rid1">1,3,5</a>]. The syndrome has been described following intentional overdose [<a href="#rid6">6,7</a>], and even in post-cardiac arrest patients treated with therapeutic hypothermia [<a href="#rid8">8</a>].</p><p>The selective serotonin reuptake inhibitors (SSRIs) are perhaps the most commonly implicated group of medications associated with serotonin syndrome. The United States’ Toxic Exposure Surveillance System consistently reports tens of thousands of exposures to SSRIs, many of which involve serotonin syndrome [<a href="#rid9">9</a>]. Notably, SSRIs are less commonly associated with causing severe serotonin syndrome compared with medications that inhibit monoamine oxidase (MAO)  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>) [<a href="#rid10">10</a>]. The serotonin-norepinephrine reuptake inhibitors (SNRIs; eg, <a class="drug drug_general" data-topicid="8944" href="/z/d/drug information/8944.html" rel="external">desvenlafaxine</a>, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) are slightly more likely to cause serotonin syndrome compared with SSRIs, but several-fold less likely compared with an MAOI co-ingestion [<a href="#rid11">11</a>].</p><p>However, the true incidence of serotonin syndrome may be under-represented in such figures for a number of reasons. Manifestations may be wrongly attributed to another cause, mild cases may be dismissed, or clinicians may not suspect the condition. Ingestion of multiple stimulants (eg, amphetamine with serotonergic agents) can cause a combination of excitatory toxidromes  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 3</a>) that might not be easily classified as pure serotonin toxicity. Many reports exist in the literature misattributing nonspecific signs and symptoms without a clear precipitating etiology to serotonin syndrome [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>In the central nervous system, serotonin modulates attention, behavior, and thermoregulation. In the peripheral nervous system, serotonin is produced primarily by intestinal enterochromaffin cells and is involved in regulating gastrointestinal motility, vasoconstriction, uterine contraction, and bronchoconstriction [<a href="#rid3">3</a>]. Serotonin is also found in platelets where it promotes platelet aggregation.</p><p>Stimulation of the postsynaptic 5-HT1A and 5-HT2A receptors has been implicated in serotonin syndrome [<a href="#rid12">12</a>], but no single receptor is solely responsible [<a href="#rid1">1</a>]. Serotonin syndrome may result from any combination of drugs that has the net effect of increasing serotonergic neurotransmission  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>). The syndrome is classically associated with the simultaneous administration of two serotonergic agents, but it can occur after initiation of a single serotonergic drug or increasing the dose of a serotonergic drug in individuals who are particularly sensitive to serotonin. Episodes of serotonin syndrome involving a monoamine oxidase inhibitor (MAOI) may be more severe and more often lead to adverse outcomes, including death [<a href="#rid13">13,14</a>]. Although counterintuitive, serotonergic agonists that have their effect directly on postsynaptic 5-HT receptors (eg, <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">buspirone</a>, LSD, triptans) are less likely to cause severe or classic serotonin toxicity as compared with drug-drug interactions or MAOIs [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H233678580"><span class="h2">Overview and principles of evaluation</span><span class="headingEndMark"> — </span>The diagnosis of serotonin syndrome is made solely on clinical grounds. Therefore, a detailed history and thorough physical and neurologic examinations are essential.</p><p>Serotonin syndrome encompasses a spectrum of disease where the intensity of clinical findings is thought to reflect the degree of serotonergic activity [<a href="#rid10">10</a>]. Mental status changes can include anxiety, restlessness, disorientation, and agitated delirium [<a href="#rid15">15</a>]. Patients may startle easily. Autonomic manifestations can include diaphoresis, tachycardia, hyperthermia, hypertension, vomiting, and diarrhea [<a href="#rid3">3</a>]. Neuromuscular hyperactivity can manifest as tremor, myoclonus, hyperreflexia, and bilateral Babinski sign. Hyperreflexia and clonus are particularly common; these findings, as well as rigidity, are more often pronounced in the lower extremities [<a href="#rid3">3</a>]. In severe cases, muscle rigidity may mask myoclonus and hyperreflexia. While uncommon, fatal cases of serotonin syndrome are associated with hyperthermia and seizure, the latter of which is often a preterminal event [<a href="#rid16">16</a>]. Should a seizure occur in what is thought to be mild or moderate serotonin syndrome, the clinician should consider other causes. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Questions remain regarding the exact point at which serotonergic signs associated with therapeutic drug administration become the toxic reaction known as serotonin syndrome [<a href="#rid10">10</a>]. The transition point likely depends upon an assessment of the risks and benefits of therapy. As an example, an individual treated for major depression with a serotonergic agent may develop mild tremor and hyperreflexia. Although technically meeting the diagnostic criteria for serotonin syndrome, the patient may benefit more (ie, be significantly less depressed) with continued administration of the agent, even though it produces obvious but tolerable signs of serotonergic excess. However, clinicians should be extremely careful <strong>not to add other serotonergic drugs</strong> to the regimen of such a patient and must remain vigilant for any worsening in condition.</p><p class="headingAnchor" id="H5"><span class="h2">History</span><span class="headingEndMark"> — </span>The patient's history should include a detailed description of prescription drugs, over-the-counter medications, illicit substances, and dietary supplements used, as well as any change in dosing and schedule  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>). Clinicians should ask about the dose, formulation (eg, sustained release), and any recent changes in medications. Episodes of serotonin syndrome involving a monoamine oxidase inhibitor, as compared with a selective serotonin reuptake inhibitor (SSRI), may be more severe and more often lead to adverse outcomes, including death [<a href="#rid13">13,14</a>].</p><p>A description of symptoms, their onset, and their rate of change is also important [<a href="#rid1">1</a>]. The majority of cases of serotonin syndrome present within 24 hours, and most within six hours, of a change in dose or initiation of a drug [<a href="#rid3">3</a>].</p><p>Patients with intentional ingestions often develop greater toxicity than those with accidental exposures, so it is important to ask the patient directly about his or her intent. Information obtained from the overdose patient is often unreliable, however, and confirmation should be sought. Additional history, including comorbid conditions and signs and symptoms, should be elicited from the patient, family members, friends, emergency medical services (EMS) personnel, and police. A general approach to management of the poisoned patient is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Typical vital sign abnormalities include tachycardia and hypertension, but severe cases may develop hyperthermia and dramatic swings in pulse and blood pressure. Pertinent physical examination findings may include [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthermia</p><p class="bulletIndent1"><span class="glyph">●</span>Agitation</p><p class="bulletIndent1"><span class="glyph">●</span>Slow, continuous, horizontal eye movements (referred to as ocular clonus)</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated pupils</p><p class="bulletIndent1"><span class="glyph">●</span>Tremor</p><p class="bulletIndent1"><span class="glyph">●</span>Akathisia</p><p class="bulletIndent1"><span class="glyph">●</span>Deep tendon hyperreflexia (common)</p><p class="bulletIndent1"><span class="glyph">●</span>Inducible or spontaneous muscle clonus (common)</p><p class="bulletIndent1"><span class="glyph">●</span>Muscle rigidity</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral Babinski signs</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mucus membranes</p><p class="bulletIndent1"><span class="glyph">●</span>Flushed skin and diaphoresis </p><p class="bulletIndent1"><span class="glyph">●</span>Increased bowel sounds  </p><p></p><p>Neuromuscular findings are typically more pronounced in the lower extremities.</p><p class="headingAnchor" id="H233678730"><span class="h1">LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>Serotonin syndrome is a clinical diagnosis; serum serotonin concentrations do not correlate with clinical findings, and no laboratory test confirms the diagnosis [<a href="#rid3">3</a>]. Nevertheless, some nonspecific laboratory findings may develop, including an elevated white blood cell count, elevated creatine phosphokinase, and decreased serum bicarbonate concentration. </p><p>Patients with severe disease may develop severe complications, including disseminated intravascular coagulation, rhabdomyolysis, metabolic acidosis, renal failure, myoglobinuria, and acute respiratory distress syndrome [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults"</a>.)</p><p>In order to narrow the differential diagnosis and to monitor for potential complications, particularly in severely ill patients, the following studies may be necessary: </p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Basic serum electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>BUN and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Creatine phosphokinase</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic transaminase concentrations</p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation studies</p><p class="bulletIndent1"><span class="glyph">●</span>Blood culture</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis and urine culture</p><p class="bulletIndent1"><span class="glyph">●</span>Plain chest radiograph</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid analysis and culture</p><p class="bulletIndent1"><span class="glyph">●</span>Head computed tomography (CT)</p><p></p><p>In patients whose overdose was intentional, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> and salicylate concentrations should be measured and an electrocardiogram evaluated for signs of toxicity from other agents. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Electrocardiography'</a> and  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Other laboratory studies'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS AND DIAGNOSTIC CRITERIA</span><span class="headingEndMark"> — </span>Serotonin syndrome is diagnosed on the basis of clinical findings. We suggest diagnosing serotonin syndrome using the Hunter Toxicity Criteria Decision Rules  (<a class="graphic graphic_algorithm graphicRef138424" href="/z/d/graphic/138424.html" rel="external">algorithm 1</a>) [<a href="#rid17">17</a>]. To fulfill the Hunter Criteria, a patient must have the presence of a serotonergic agent and meet <strong>one</strong> of the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous clonus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inducible clonus <strong>plus</strong> agitation or diaphoresis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ocular clonus <strong>plus</strong> agitation or diaphoresis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tremor <strong>plus</strong> hyperreflexia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertonia <strong>plus</strong> temperature above 38ºC PLUS ocular clonus or inducible clonus</p><p></p><p>Serotonin syndrome is typically not a diagnosis of exclusion if the Hunter Criteria are met. However, patients on a stable dose of a serotonergic agent are unlikely to develop serotonin syndrome. Therefore, authorities suggested that the "presence of serotonergic agent" be defined as one of the following to make a definitive diagnosis [<a href="#rid10">10</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Overdose with a serotonergic agent <strong>except</strong> a direct serotonin receptor agonist  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-drug interaction of two serotonergic agents <strong>except</strong> when both are direct serotonin receptor agonists</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiation or increase in dose of a serotonergic agent or agent that decreases metabolism of serotonergic agent</p><p></p><p>If none of these are present, then serotonin syndrome should be considered a diagnosis of exclusion, and other etiologies should be excluded. A mixed excitatory toxidrome  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 3</a>) may be responsible in the setting of a polysubstance ingestion.</p><p>Several sets of diagnostic criteria have been developed to define serotonin syndrome, of which the Hunter Criteria are most accurate (84 percent sensitive and 97 percent specific when compared with the gold standard of diagnosis by a medical toxicologist). In a comparison with the original Sternbach Criteria, the Hunter Criteria performed with greater accuracy and were less likely to miss early, mild, or subacute forms of serotonin syndrome [<a href="#rid10">10,17</a>]. </p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of serotonin syndrome includes neuroleptic malignant syndrome (NMS), anticholinergic toxicity, malignant hyperthermia, intoxication from sympathomimetic agents, sedative-hypnotic (eg, alcohol, benzodiazepine, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">baclofen</a>) withdrawal, thyroid storm, acute extrapyramidal syndromes (eg, dystonic reaction), meningitis, and encephalitis. </p><p>Serotonin syndrome is often misdiagnosed as NMS, but the two can readily be distinguished on the basis of history, examination findings, and clinical course  (<a class="graphic graphic_table graphicRef58227" href="/z/d/graphic/58227.html" rel="external">table 4</a>) [<a href="#rid12">12</a>]. NMS develops over days to weeks [<a href="#rid12">12</a>], whereas serotonin syndrome develops over 24 hours [<a href="#rid3">3</a>]. Serotonin syndrome is characterized by neuromuscular hyperreactivity (tremor, hyperreflexia, myoclonus), while NMS involves sluggish neuromuscular responses (rigidity, bradyreflexia). Hyperreflexia and myoclonus are rare in NMS [<a href="#rid12">12</a>]. In addition, resolution of NMS typically requires an average of nine days, compared with less than 24 hours (usually) for resolution of serotonin syndrome [<a href="#rid12">12</a>]. Hyperthermia, altered mental status, muscle rigidity, leukocytosis, elevated creatine phosphokinase, elevated hepatic transaminases, and metabolic acidosis are seen in severe cases of both conditions, which highlight the necessity of a thorough history and physical examination. (See  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p>Anticholinergic toxicity classically presents with hyperthermia, agitation, altered mental status, mydriasis, dry mucous membranes, urinary retention, and decreased bowel sounds after the use of an anticholinergic agent. In contrast with serotonin syndrome, muscular tone and reflexes are normal in anticholinergic poisoning  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.)</p><p>Extrapyramidal syndromes, such as an acute dystonic reaction, involve involuntary contraction of major muscle groups. Acute dystonia precipitated by antipsychotic medications is usually rapid in onset and is characterized by torticollis, retrocollis, oculogyric crisis, and opisthotonos. Compared with serotonin syndrome, dystonic reactions have sluggish neuromuscular responses (ie, rigidity) and muscle contractions that are asymmetric (eg, torticollis is not directed towards midline) and rapidly improve with <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> or <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">benztropine</a> administration. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Movement and motor symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/315.html" rel="external">"First-generation (typical) antipsychotic medication poisoning", section on 'Acute extrapyramidal syndromes'</a>.)</p><p>Malignant hyperthermia occurs in susceptible individuals exposed to halogenated volatile anesthetics and depolarizing muscle relaxants (eg, <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>). It classically presents with increased concentrations of end-tidal carbon dioxide, rigor mortis-like muscle rigidity, tachycardia, hyperthermia, and acidosis [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a> and  <a class="medical medical_review" href="/z/d/html/403.html" rel="external">"Susceptibility to malignant hyperthermia: Evaluation and management"</a>.)</p><p>Serotonin syndrome may be distinguished from other causes of agitated delirium on the basis of neuromuscular findings. Whereas patients with serotonin syndrome show signs of neuromuscular activation (eg, tremor, hyperreflexia and clonus that are greater in the lower extremities, ocular clonus, and increased muscle tone), patients with sympathomimetic toxicity, sedative-hypnotic withdrawal, or infections of the central nervous system typically lack these findings. (See  <a class="medical medical_review" href="/z/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">"Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Clinical features of overdose'</a> and  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis", section on 'Clinical presentation and course'</a> and  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p>The symptoms and signs of serotonin syndrome and thyroid storm can overlap. In most cases, the two conditions are readily distinguished based on the history and clinical findings, and no additional testing is necessary. Patients in thyroid storm typically have a known history of thyroid disease and a discrete inciting event (eg, surgery, infection) along with clinical findings suggesting the diagnosis, such as hyperpyrexia, palpable goiter, cardiovascular dysfunction (eg, tachydysrhythmia, signs of heart failure), agitated mental state, and tremor. In the rare circumstance when it is difficult to distinguish between the two conditions (eg, patient with a history of thyroid disease also taking a serotonergic medication), obtaining thyroid studies may be helpful. (See  <a class="medical medical_review" href="/z/d/html/7885.html" rel="external">"Thyroid storm"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H233678965"><span class="h2">Key principles</span><span class="headingEndMark"> — </span>A summary table to facilitate the emergent management of serotonin syndrome is provided  (<a class="graphic graphic_table graphicRef73400" href="/z/d/graphic/73400.html" rel="external">table 1</a>). Five principles are central to the management of serotonin syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of all serotonergic agents  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Supportive care aimed at normalization of vital signs</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation with benzodiazepines</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of serotonin antagonists</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of the need to resume use of causative serotonergic agents after resolution of symptoms</p><p></p><p>Application of these principles varies with the severity of illness. In mild cases, discontinuation of inciting medications, supportive care, and sedation with benzodiazepines are generally sufficient. Moderately ill patients require more aggressive treatment of autonomic instability and possibly treatment with a serotonin antagonist (see <a class="local">'Antidote: Cyproheptadine'</a> below). Hyperthermic patients (&gt;41.1°C) are critically ill and often require neuromuscular paralysis and tracheal intubation.</p><p>Common management pitfalls include failure to recognize serotonin syndrome, misdiagnosis, and failure to understand serotonin syndrome's potentially rapid rate of progression (see <a class="local">'Clinical features'</a> above). Even if the diagnosis remains unclear, the clinician should withhold serotonergic agents and provide aggressive supportive care, anticipating the need for interventions before the patient's condition deteriorates. In a patient with an excitatory toxidrome  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 3</a>), managing agitation and neuromuscular hyperactivity is required even if the patient does not meet strict diagnostic criteria for serotonin syndrome.</p><p>Serotonin syndrome often resolves within 24 hours of discontinuing the serotonergic agent and initiating care, but drugs with long half-lives or active metabolites may cause symptoms to persist [<a href="#rid1">1</a>]. Irreversible monoamine oxidase inhibitors (MAOIs) carry the greatest risk, and symptoms can persist for several days. Selective serotonin reuptake inhibitors (SSRIs) may contribute to the development of serotonin syndrome up to several weeks after the drug has been discontinued; the half-life of <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> is one week and that of its metabolite norfluoxetine is up to 2.5 weeks [<a href="#rid19">19</a>]. Although the patient may not exhibit symptoms of serotonin syndrome while taking fluoxetine, care should be taken when administering another serotonergic agent after discontinuing this or any other SSRI.</p><p>As with any toxic exposure, consultation with a medical toxicologist, clinical pharmacologist, or poison control center can provide valuable assistance with clinical decision-making. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h2">Supportive care and sedation</span><span class="headingEndMark"> — </span>Supportive care is the mainstay of therapy and includes the administration of oxygen and intravenous (IV) fluids, continuous cardiac monitoring, and correction of vital signs. Clinicians should provide sufficient oxygen to maintain the oxygen saturation ≥ 94 percent, and give IV crystalloid to treat volume depletion, and to some extent hyperthermia.</p><p>Chemical restraint is greatly preferred to physical restraint for agitated patients; physical restraints may cause isometric muscle contractions leading to profound lactic acidosis and hyperthermia [<a href="#rid1">1</a>]. Sedation with benzodiazepines is important for controlling agitation as well as correcting mild increases in blood pressure and heart rate. <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">Diazepam</a> prolongs survival in a rat model of serotonin syndrome, but no specific agent has been studied in humans [<a href="#rid20">20</a>]. Regardless of the benzodiazepine selected, the clinician should give standard doses to begin therapy and titrate further treatment to effect, the goals being adequate patient sedation (not somnolence) and normal vital signs. </p><p>We treat patients with significant agitation (eg, those who do not respond immediately to verbal interventions) with IV benzodiazepines (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 2 to 4 mg IV or <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> 5 to 10 mg IV; pediatric dosing of lorazepam 0.05 to 0.1 mg/kg IV or intramuscular). These doses can be repeated every 8 to 10 minutes based upon patient response. Butyrophenones (eg, <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">droperidol</a> and <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>) should be avoided; these drugs have anticholinergic properties that inhibit sweating and dissipation of body heat.  </p><p class="headingAnchor" id="H12"><span class="h2">Autonomic instability</span><span class="headingEndMark"> — </span>Management of autonomic instability may be difficult since severely intoxicated patients often exhibit large and rapid changes in blood pressure and heart rate. Consequently, patients with severe hypertension and tachycardia should be treated with short-acting agents, such as <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> [<a href="#rid1">1</a>]. Dosing of these short-acting cardiovascular agents should be titrated to maintain autonomic stability; longer-acting agents, such as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, should be avoided. </p><p>Hypotension from MAOIs in patients with serotonin syndrome should be treated with low doses of direct-acting sympathomimetic amines, such as <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, or norepinephrine [<a href="#rid1">1</a>]. Indirect agents (eg, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>) should be avoided because they are metabolized to epinephrine and norepinephrine; when monoamine oxidase is inhibited, epinephrine and norepinephrine production at the cellular level is not controlled, possibly leading to an exaggerated hemodynamic response [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Hyperthermia</span><span class="headingEndMark"> — </span>Control of hyperthermia is critical and involves eliminating excessive muscle activity. Aggressive and effective control of hyperthermia can potentially minimize several severe complications of serotonin syndrome (eg, seizures, coma, disseminated intravascular coagulation, hypotension, ventricular tachycardia, and metabolic acidosis) [<a href="#rid12">12</a>]. Standard treatments for hyperthermia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Cooling measures and temperature monitoring'</a>.)</p><p>Patients whose temperature is above 41.1°C require immediate sedation, paralysis, and tracheal intubation [<a href="#rid1">1</a>]. Standard rapid sequence intubation (RSI) using an induction and paralytic agent should be performed. <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">Etomidate</a> (0.3 mg/kg IV) and <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> (1.5 to 2 mg/kg IV) can generally be used; succinylcholine should be avoided in patients with possible hyperkalemia (as may occur in patients with acute renal failure or rhabdomyolysis). After intubation, paralysis can be maintained with a longer-acting nondepolarizing agent, such as <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">vecuronium</a>. Clinicians must provide adequate sedation, typically with a benzodiazepine, while the patient is paralyzed. (See  <a class="medical medical_review" href="/z/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a>.)</p><p>In hyperthermia associated with serotonin syndrome, there is no role for antipyretic agents, such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>; the increase in body temperature is not due to an alteration in the hypothalamic temperature set point, but rather an increase in muscular activity [<a href="#rid1">1</a>]. In cases where the etiology of the patient's hyperthermia is unclear initially and infection remains a possibility, empiric administration of an initial dose of antibiotics, following collection of appropriate cultures, is prudent while cooling measures are implemented.</p><p class="headingAnchor" id="H14"><span class="h2">Antidote: Cyproheptadine</span><span class="headingEndMark"> — </span>If benzodiazepines and supportive care fail to improve agitation and correct vital signs, we suggest antidotal therapy with <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a> [<a href="#rid21">21</a>]. Cyproheptadine is a histamine-1 receptor antagonist with nonspecific 5-HT1A and 5-HT2A antagonistic properties [<a href="#rid21">21</a>]. It also has weak anticholinergic activity.</p><p><a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">Cyproheptadine</a> is available in 4 mg tablets or 2 mg/5 mL syrup [<a href="#rid12">12</a>]. When administered as an antidote for serotonin syndrome, an initial dose of 12 mg is recommended, followed by 2 mg every two hours until clinical response is seen. Cyproheptadine is only available in an oral form, but it may be crushed and given through a nasogastric or orogastric tube.</p><p><a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">Cyproheptadine</a> may lead to sedation, but this effect is consistent with the goals of management [<a href="#rid1">1</a>]. Furthermore, as a nonspecific serotonin antagonist, cyproheptadine may produce transient hypotension due to the reversal of serotonin-mediated increases in vascular tone. Such hypotension usually responds to IV fluids. Based on limited observational evidence, treatment with cyproheptadine during pregnancy is not associated with an increased risk of congenital abnormalities [<a href="#rid12">12</a>].</p><p>Definitive evidence of <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a>'s effectiveness is lacking. A small study used PET scan to assess 5-HT2 blockade in two volunteers after taking cyproheptadine (12 mg and 18 mg per day for six days). At 12 mg/day, there was 85 percent blockade and at 18 mg/day there was over 95 percent blockade of 5-HT2 receptors in the prefrontal cortex [<a href="#rid22">22</a>]. In addition, many reports describe the successful use of cyproheptadine to treat serotonin syndrome [<a href="#rid21">21,23-28</a>]. The majority of these patients received cyproheptadine at an initial dose of 8 mg, while fewer patients responded to as little as 4 mg and some had no response to as much as 16 mg.</p><p class="headingAnchor" id="H15"><span class="h2">Other antidotes</span><span class="headingEndMark"> — </span>Antipsychotic agents with 5-HT2A antagonist activity, such as <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>, have been considered for antidotal treatment, but their efficacy is unproven and we do <strong>not</strong> recommend their use [<a href="#rid1">1</a>]. Chlorpromazine can cause orthostatic hypotension, although this is generally not an issue with serotonin syndrome, in which hypertension is common. Chlorpromazine can also increase hyperthermia.</p><p>Treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>, or <a class="drug drug_general" data-topicid="9322" href="/z/d/drug information/9322.html" rel="external">dantrolene</a> is <strong>not</strong> recommended. Propranolol has a long duration of action, may cause prolonged hypotension, and can mask tachycardia that can be used to monitor the effectiveness of treatment. Bromocriptine, a serotonin agonist, may exacerbate serotonin syndrome [<a href="#rid1">1</a>]. Dantrolene has no effect on survival in animal models and is ineffective in patients with severe temperature elevation not caused by skeletal muscle receptor abnormalities. (See  <a class="medical medical_review" href="/z/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis"</a> and  <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome", section on 'Medical therapy'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">DISPOSITION AND PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with severe serotonin syndrome (eg, hyperthermia, autonomic instability, agitated delirium) require care in an intensive care unit. Those with moderate symptoms should be admitted for observation and placed on a cardiac monitor until symptoms resolve. Symptoms usually resolve within 24 hours of discontinuing the serotonergic agent and initiating care, but drugs with long durations of action or active metabolites may cause prolonged symptoms [<a href="#rid1">1</a>]. Mild cases may be observed for four to six hours. If during that period the patient's mental status and vital signs remain normal, there is no increase in clonus or deep tendon reflexes, and close follow-up is assured, the patient may be discharged home.</p><p>It merits reiteration that serotonin syndrome manifests a broad spectrum of clinical severity. Particularly in mild cases, clinicians must weigh benefits and risks when determining treatment and whether to continue the causative agent. (See <a class="local">'Clinical features'</a> above.)</p><p>Prognosis is generally favorable, as long as the entity is recognized and complications are treated appropriately.</p><p class="headingAnchor" id="H964538553"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H18"><span class="h2">Pediatrics</span><span class="headingEndMark"> — </span>Serotonin syndrome in the pediatric population parallels that in the adult population, with similar pathophysiology and manifestations. Any drug or drug combination that increases serotonergic neurotransmission can produce the syndrome  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>). The same diagnostic criteria, characterized by increased neuromuscular activity, are used in the pediatric population. Hyperreflexia, clonus, and hyperthermia remain important findings. (See <a class="local">'Diagnosis and diagnostic criteria'</a> above.)</p><p>Although multiple case reports have been published, several obstacles make the diagnosis of serotonin syndrome more difficult in pediatric patients [<a href="#rid29">29-32</a>]. Children may not be able to communicate vague symptoms; clinicians may not consider the syndrome a pediatric problem; and adolescents may be reluctant to disclose recreational drug use, which may include serotonergic agents, such as methylenedioxymethamphetamine (MDMA; "ecstasy") or <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/302.html" rel="external">"MDMA (ecstasy) intoxication"</a> and  <a class="medical medical_review" href="/z/d/html/6488.html" rel="external">"Dextromethorphan misuse and poisoning: Clinical features and diagnosis"</a>.)</p><p>The fundamental principles of serotonin syndrome management remain unchanged in pediatrics. Any serotonergic agent is discontinued. Supportive care is provided, the goals being adequate patient sedation and normal vital signs. Standard interventions include oxygen, intravenous (IV) fluids, and continuous cardiac monitoring. Autonomic instability and hyperthermia require aggressive treatment. Sedation with weight-based doses of benzodiazepines is recommended for the treatment of agitation. (See <a class="local">'Management'</a> above.)</p><p>In pediatric patients with severe symptoms, serotonergic antagonists can be given; <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a> may be used in pediatric patients with a dose of 0.25 mg/kg/day divided every six hours. Doses should be titrated to maintain adequate sedation. General dosing is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Children younger than two years can be given approximately 0.06 mg/kg per dose every six hours, if needed (not to exceed 0.25 mg/kg/day).</p><p class="bulletIndent1"><span class="glyph">●</span>Children two to six years can be given 2 mg every six hours, if needed (not to exceed 12 mg/day).</p><p class="bulletIndent1"><span class="glyph">●</span>Children 7 to 14 years can be given 4 mg every six hours, if needed (not to exceed 16 mg/day).</p><p></p><p>Pediatric patients with severe serotonin syndrome require management in an intensive care unit. Pediatric patients with mild to moderate symptoms should be placed on a cardiac monitor and admitted for observation. If serotonin syndrome is recognized and complications are treated appropriately, the prognosis is generally favorable.</p><p>In addition to cases in the general pediatric population, there are rare reports of neonates with symptoms resembling serotonin syndrome. One small study showed that infants exposed to SSRIs late in pregnancy were at increased risk for adverse central nervous system effects [<a href="#rid33">33</a>]. The most prominent findings were restlessness, tremor, and rigidity; myoclonus and hyperreflexia occurred less often. Symptoms appeared to subside quickly without any specific treatment [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3669416142"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>Management of serotonin toxicity in older adults is similar to other populations. However, older adults are at potentially increased risk of developing serotonin toxicity due to drug interactions from polypharmacy. General issues with polypharmacy in older adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3013.html" rel="external">"Drug prescribing for older adults", section on 'Polypharmacy'</a>.)   </p><p>Older adults who take multiple medications that increase serotonergic neurotransmission  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>) are at increased risk [<a href="#rid34">34,35</a>]. In United States adults, antidepressant use increases with age; 19 percent of adults 60 years and older reported taking an antidepressant during 2015 to 2018 [<a href="#rid36">36</a>]. In a study that reviewed the medication lists of 6545 ambulatory patients 60 years and older followed in one clinic, the prevalence of potential multidrug interactions was 1.3 percent [<a href="#rid37">37</a>]. Among those, psychotropics were the most common (35 percent) medications that could contribute to interactions, and serotonin toxicity would be the outcome in approximately 20 percent.</p><p><a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">Tramadol</a>, a strongly serotonergic opioid that can cause serotonin toxicity by itself or combined with other serotonergic agents, is often prescribed to older adults. A study of the United States National Hospital Ambulatory Medical Care Survey found that from 2007 to 2018, tramadol prescribing during emergency department visits increased from 1.7 to 2.9 percent [<a href="#rid38">38</a>]. Patients 55 years and older had the largest increase, which was almost threefold. Multiple case reported describe tramadol precipitating serotonin toxicity in older adults [<a href="#rid39">39-43</a>].</p><p>As compared with other age groups, older adults who develop serotonin toxicity may be more likely to go undiagnosed. Many of the signs and symptoms of serotonin excess, such as generalized weakness, confusion, hallucinations, fever, diaphoresis, tachypnea, and tachycardia, are nonspecific and can be misattributed to infection, dehydration, and other metabolic processes in older adults. Tremor can be mistaken for rigors [<a href="#rid44">44</a>]. A study of 309 consecutive patients admitted to one intensive care unit found that 8 percent (mean age 52 years; 14/24 were ≥55 years) met the Hunter Toxicity Criteria  (<a class="graphic graphic_algorithm graphicRef138424" href="/z/d/graphic/138424.html" rel="external">algorithm 1</a>) for serotonin syndrome; none of the patients were recognized to have this diagnosis until examined by the investigators [<a href="#rid45">45</a>].  </p><p>In an older adult taking one or more serotonergic agents who presents with altered mental status, fever, or signs of autonomic hyperactivity, we examine the lower extremities specifically for tremor, hyperreflexia, and clonus. The same diagnostic criteria, characterized by increased neuromuscular activity, are used in older adults. Tremor and hyperreflexia are important findings and common in older adults with serotonin excess [<a href="#rid34">34</a>]. (See <a class="local">'Diagnosis and diagnostic criteria'</a> above.)  </p><p class="headingAnchor" id="H19"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Serotonin syndrome can be avoided by applying pharmacologic principles, educating clinicians, and modifying prescription practices [<a href="#rid1">1</a>]. Multi-drug regimens should be avoided, if possible. <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">Tramadol</a>, <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, and <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">dextromethorphan</a> are strongly serotonergic opioids and should be avoided in patients taking other serotonergic agents [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H9902974"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3548468086"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Once serotonin syndrome occurs, a medical toxicologist, clinical pharmacologist, or poison control center should be consulted for assistance. Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H876659786"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.) </p><p class="headingAnchor" id="H3628545"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87578.html" rel="external">"Patient education: Serotonin syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Serotonin syndrome is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system due to serotonergic agent therapeutic use, inadvertent interactions between drugs, and intentional self-poisoning. Monoamine oxidase inhibitors (MAOIs) are associated with the most severe cases and direct serotonin receptor agonists with the mildest cases. (See <a class="local">'Pharmacology and cellular toxicology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> –<strong> </strong>Serotonin syndrome encompasses a spectrum of disease where the intensity of clinical findings is thought to reflect the degree of serotonergic activity. Most<strong> </strong>cases of serotonin syndrome present within 24 hours of a change or initiation of a serotonergic drug  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 2</a>). Typical vital sign abnormalities include tachycardia and hypertension, but severe cases may develop hyperthermia and rapid, dramatic swings in pulse and blood pressure. Patients can manifest agitation, ocular clonus, tremor, akathisia, deep tendon hyperreflexia, inducible or spontaneous clonus, muscle rigidity, dilated pupils, and diaphoresis. Neuromuscular findings are typically more pronounced in the lower extremities. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Serotonin syndrome is a clinical diagnosis. The Hunter Criteria are the most accurate diagnostic criteria; a patient must have the presence of a serotonergic agent and meet <strong>one</strong> of the following conditions (see <a class="local">'Diagnosis and diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spontaneous clonus</p><p class="bulletIndent2"><span class="glyph">•</span>Inducible clonus <strong>plus</strong> agitation or diaphoresis</p><p class="bulletIndent2"><span class="glyph">•</span>Ocular clonus <strong>plus</strong> agitation or diaphoresis</p><p class="bulletIndent2"><span class="glyph">•</span>Tremor <strong>plus</strong> hyperreflexia</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertonia <strong>plus</strong> temperature above 38°C <strong>plus</strong> ocular clonus or inducible clonus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – No laboratory test confirms the diagnosis; serotonin concentrations do not correlate with clinical findings. Additional diagnostic studies are used to exclude other etiologies and monitor potential complications. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment depends on the severity of illness and starts with discontinuing all serotonergic agents. In mild cases, supportive care and sedation with benzodiazepines is generally sufficient. Moderately ill patients require more aggressive treatment of autonomic instability and possibly treatment with a serotonin antagonist. Hyperthermic patients are critically ill and often require paralysis and endotracheal intubation. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supportive care is the mainstay of therapy. All patients are treated with oxygen to maintain oxygen saturation (SpO<sub>2</sub>) ≥94 percent, intravenous (IV) fluids for volume depletion, continuous cardiac monitoring, and correction of abnormal vital signs. Severely intoxicated patients often exhibit rapid, dramatic changes in vital signs. (See <a class="local">'Supportive care and sedation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with severe hypertension and tachycardia, we suggest treatment with short-acting agents, such as <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>, <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, or <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with hypotension from MAOIs, we suggest treatment with low doses of direct-acting sympathomimetic amines such as <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>, or norepinephrine (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We recommend that indirect agents (eg, <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>) <strong>not</strong> be used (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Autonomic instability'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Control of hyperthermia is critical and involves eliminating excessive muscle activity. In patients whose temperature is above 41.1°C, we recommend treatment with immediate sedation, paralysis, and tracheal intubation in addition to external cooling measures as compared with external cooling measures alone (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Antipyretic agents (eg, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>) are ineffective and should <strong>not</strong> be used for serotonin syndrome. (See <a class="local">'Hyperthermia'</a> above and  <a class="medical medical_review" href="/z/d/html/176.html" rel="external">"Severe nonexertional hyperthermia (classic heat stroke) in adults", section on 'Cooling measures and temperature monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest sedation with benzodiazepines for controlling agitation as well as correcting mild increases in blood pressure and heart rate (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Supportive care and sedation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients for whom benzodiazepines and supportive care fail to improve agitation and correct vital signs, we suggest treatment with <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a>, an antagonist at histamine and serotonin receptors (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The initial dose is 12 mg, followed by 2 mg every two hours until clinical response is seen. Cyproheptadine is only available in an oral form, but it may be crushed and given through a nasogastric tube. (See <a class="local">'Antidote: Cyproheptadine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disposition and prognosis</strong> – Symptoms usually resolve within 24 hours of discontinuing the serotonergic agent. Patients with mild or moderate symptoms should be monitored until symptoms resolve. Patients with severe serotonin toxicity (eg, hyperthermia, autonomic instability, agitated delirium) require care in an intensive care unit. (See <a class="local">'Disposition and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1542779258"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stephen J Traub, MD, former section editor of the toxicology program, for 20 years of dedicated service.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112.</a></li><li><a class="nounderline abstract_t">Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003; 168:1439.</a></li><li><a class="nounderline abstract_t">Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79:201.</a></li><li><a class="nounderline abstract_t">Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995; 45:219.</a></li><li><a class="nounderline abstract_t">Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705.</a></li><li class="breakAll">De Roos FJ. Drug interactions: Combinations that can kill your patients. American College of Emergency Physicians Scientific Assembly lecture, September 26, 2005, Washington Convention Center.</li><li><a class="nounderline abstract_t">Canan F, Korkmaz U, Kocer E, et al. Serotonin syndrome with paroxetine overdose: a case report. Prim Care Companion J Clin Psychiatry 2008; 10:165.</a></li><li><a class="nounderline abstract_t">Fugate JE, White RD, Rabinstein AA. Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series. Resuscitation 2014; 85:774.</a></li><li><a class="nounderline abstract_t">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50:911.</a></li><li><a class="nounderline abstract_t">Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila) 2022; 60:143.</a></li><li><a class="nounderline abstract_t">Cooper J, Duffull SB, Isbister GK. Predicting serotonin toxicity in serotonin reuptake inhibitor overdose. Clin Toxicol (Phila) 2023; 61:22.</a></li><li><a class="nounderline abstract_t">Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin 1997; 13:763.</a></li><li><a class="nounderline abstract_t">Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28:205.</a></li><li><a class="nounderline abstract_t">Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007; 152:946.</a></li><li><a class="nounderline abstract_t">Ganetsky M, Brush E. Serotonin syndrome—what have we learned. Clin Ped Emerg Med 2005; 6:103.</a></li><li><a class="nounderline abstract_t">Prakash S, Rathore C, Rana K, Prakash A. Fatal serotonin syndrome: a systematic review of 56 cases in the literature. Clin Toxicol (Phila) 2021; 59:89.</a></li><li><a class="nounderline abstract_t">Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96:635.</a></li><li><a class="nounderline abstract_t">Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003; 17:519.</a></li><li><a class="nounderline abstract_t">Martin TG. Serotonin syndrome. Ann Emerg Med 1996; 28:520.</a></li><li><a class="nounderline abstract_t">Nisijima K, Shioda K, Yoshino T, et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 2003; 43:155.</a></li><li><a class="nounderline abstract_t">Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998; 16:615.</a></li><li><a class="nounderline abstract_t">Kapur S, Zipursky RB, Jones C, et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 1997; 154:884.</a></li><li><a class="nounderline abstract_t">Baigel GD. Cyproheptadine and the treatment of an unconscious patient with the serotonin syndrome. Eur J Anaesthesiol 2003; 20:586.</a></li><li><a class="nounderline abstract_t">Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999; 13:100.</a></li><li><a class="nounderline abstract_t">Horowitz BZ, Mullins ME. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr Emerg Care 1999; 15:325.</a></li><li><a class="nounderline abstract_t">Kolecki P. Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks. J Toxicol Clin Toxicol 1997; 35:211.</a></li><li><a class="nounderline abstract_t">Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331:1021.</a></li><li><a class="nounderline abstract_t">McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother 2001; 35:870.</a></li><li><a class="nounderline abstract_t">Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry 2004; 43:790.</a></li><li><a class="nounderline abstract_t">Pao M, Tipnis T. Serotonin syndrome after sertraline overdose in a 5-year-old girl. Arch Pediatr Adolesc Med 1997; 151:1064.</a></li><li><a class="nounderline abstract_t">Godinho EM, Thompson AE, Bramble DJ. Neuroleptic withdrawal versus serotonergic syndrome in an 8-year-old child. J Child Adolesc Psychopharmacol 2002; 12:265.</a></li><li><a class="nounderline abstract_t">Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med 1999; 33:457.</a></li><li><a class="nounderline abstract_t">Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720.</a></li><li><a class="nounderline abstract_t">Erken N, Kaya D, Dost FS, et al. Antidepressant-induced serotonin syndrome in older patients: a cross-sectional study. Psychogeriatrics 2022; 22:502.</a></li><li><a class="nounderline abstract_t">Poeschla BD, Bartle P, Hansen KP. Serotonin syndrome associated with polypharmacy in the elderly. Gen Hosp Psychiatry 2011; 33:301.e9.</a></li><li><a class="nounderline abstract_t">Brody DJ, Gu Q. Antidepressant Use Among Adults: United States, 2015-2018. NCHS Data Brief 2020; :1.</a></li><li><a class="nounderline abstract_t">Anand TV, Wallace BK, Chase HS. Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients. BMC Geriatr 2021; 21:648.</a></li><li><a class="nounderline abstract_t">Mullins PM, Mazer-Amirshahi M, Pourmand A, et al. Tramadol Use in United States Emergency Departments 2007-2018. J Emerg Med 2022; 62:668.</a></li><li><a class="nounderline abstract_t">Ruiz de Villa A, Jones T, Lleshi A, et al. Serotonin Toxicity Precipitated by Tramadol in the Setting of Polypharmacy: A Case of Serotonin Syndrome. Cureus 2021; 13:e20059.</a></li><li><a class="nounderline abstract_t">Hardy M, Panikkar G. A Case of Serotonin Syndrome in the Setting of Dextromethorphan-Based Cough Medicine, Tramadol, and Multiple Antidepressants. Prim Care Companion CNS Disord 2020; 22.</a></li><li><a class="nounderline abstract_t">Ekşi MŞ, Turgut VU, Özcan-Ekşi EE, et al. Serotonin Syndrome Following Tramadol and Gabapentin Use After Spine Surgery. World Neurosurg 2019; 126:261.</a></li><li><a class="nounderline abstract_t">Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. J Neuropsychiatry Clin Neurosci 2012; 24:E52.</a></li><li><a class="nounderline abstract_t">Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing 2011; 40:528.</a></li><li><a class="nounderline abstract_t">Lim R, Arshad W. Underlying Serotonin Syndrome, Masked by Community-Acquired Pneumonia and Myocardial Ischemia. Am J Case Rep 2020; 21:e924109.</a></li><li><a class="nounderline abstract_t">Prakash S, Rathore C, Rana K. The prevalence of serotonin syndrome in an intensive care unit: A prospective observational study. J Crit Care 2021; 63:92.</a></li></ol></div><div id="topicVersionRevision">Topic 301 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784664" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771076" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serotonin syndrome: a brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10941349" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Serotonin syndrome. Presentation of 2 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854515" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035713" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2035713" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458731" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Serotonin syndrome with paroxetine overdose: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614188" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serotonin syndrome after therapeutic hypothermia for cardiac arrest: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23272763" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34806513" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36444913" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predicting serotonin toxicity in serotonin reuptake inhibitor overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330840" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serotonin syndrome. A clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239759" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721552" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serotonin syndrome—what have we learned</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33196298" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fatal serotonin syndrome: a systematic review of 56 cases in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925718" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14661655" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Malignant hyperthermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8909274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12620284" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696181" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment of the serotonin syndrome with cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167527" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cyproheptadine: a potent in vivo serotonin antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12884999" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cyproheptadine and the treatment of an unconscious patient with the serotonin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221364" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The serotonin syndrome and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10532660" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120894" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8084345" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of the serotonin syndrome with cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11485136" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serotonin syndrome: early management with cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213578" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serotonin syndrome and linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9343027" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serotonin syndrome after sertraline overdose in a 5-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427301" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Neuroleptic withdrawal versus serotonergic syndrome in an 8-year-old child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10092727" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Serotonin syndrome in a child after a single dose of fluvoxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860776" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35562169" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antidepressant-induced serotonin syndrome in older patients: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601732" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serotonin syndrome associated with polypharmacy in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33054926" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antidepressant Use Among Adults: United States, 2015-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34798832" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35370038" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tramadol Use in United States Emergency Departments 2007-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34987932" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serotonin Toxicity Precipitated by Tramadol in the Setting of Polypharmacy: A Case of Serotonin Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32141719" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Case of Serotonin Syndrome in the Setting of Dextromethorphan-Based Cough Medicine, Tramadol, and Multiple Antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30898741" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serotonin Syndrome Following Tramadol and Gabapentin Use After Spine Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224488" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tramadol precipitating serotonin syndrome in a patient on antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21414947" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serotonin syndrome secondary to tramadol and citalopram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32503963" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Underlying Serotonin Syndrome, Masked by Community-Acquired Pneumonia and Myocardial Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33621893" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The prevalence of serotonin syndrome in an intensive care unit: A prospective observational study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
